CRISPR and AI drug discovery platform that identifies disease-driving RNA signaling pathways at single-cell resolution.
Algen Biotechnologies uses AlgenCRISPR, a proprietary next-generation CRISPR gene modulation system, paired with AlgenBrain, an AI foundation model trained on billions of real-time gene expression changes across disease progression. The combined platform enables single-cell gene modulation at industrial scale to identify disease-driving RNA signaling pathways and discover first-in-class drugs for conditions with high unmet needs. Founded on research from Nobel Laureate Jennifer Doudna's lab. Algen Biotechnologies is a product of Algen Biotechnologies.